Lioudaki Eirini, Androvitsanea Ariadni, Petrakis Ioannis, Bakogiannis Constantinos, Androulakis Emmanuel
Renal Unit, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.
Department of Nephrology, Friedrich-Alexander University Hospital, 91054 Erlangen, Germany.
Diagnostics (Basel). 2022 Sep 27;12(10):2332. doi: 10.3390/diagnostics12102332.
Given the high cardiovascular risk accompanying end-stage kidney disease, it would be of paramount importance for the clinical nephrologist to know which screening method(s) identify high-risk patients and whether screening asymptomatic transplant candidates effectively reduces cardiovascular risk in the perioperative setting as well as in the longer term. Within this review, key studies concerning the above questions are reported and critically analyzed. The lack of unified screening criteria and of a prognostically sufficient screening cardiovascular effect for renal transplant candidates sets the foundation for a personalized patient approach in the near future and highlights the need for well-designed studies to produce robust evidence which will address the above questions.
鉴于终末期肾病伴有较高的心血管风险，临床肾病学家了解哪种筛查方法能够识别高危患者，以及筛查无症状的肾移植候选者是否能在围手术期及更长期有效降低心血管风险至关重要。在本综述中，报告并批判性分析了有关上述问题的关键研究。肾移植候选者缺乏统一的筛查标准以及预后充分的筛查心血管效应，这为在不久的将来采取个性化的患者治疗方法奠定了基础，并凸显了开展精心设计的研究以产生有力证据来解决上述问题的必要性。
